Randomized, double‐blind, placebo‐controlled phase 1 study to evaluate the safety and pharmacokinetics of high doses of ubiquinol in healthy adults
Neurology and Clinical Neuroscience · 2022-01 · 10 (1) · 14-24
DOI: 10.1111/ncn3.12566 ↗Kurz gefasst
Fachartikel in der Zeitschrift Neurology and Clinical Neuroscience, online erschienen am 07.12.2021. Verfasst von Jun Mitsui und 16 weiteren Autor:innen. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Japan Agency for Medical Research and Development.
Abstract (Originalsprache)
Background
Multiple system atrophy (MSA) is an intractable neurodegenerative disease. Higher frequencies of carriers of the V393A variant in COQ2 and lower levels of coenzyme Q10 (CoQ10) in body tissues have been reported in patients with MSA than in healthy controls. On the basis of the hypothesis that CoQ10 supplementation may slow the progression of MSA, we have been developing CoQ10 as an investigational drug for MSA.
Methods
A single‐center, randomized, double‐blind, placebo‐controlled phase 1 study of ubiquinol in healthy adult male volunteers was conducted. Participants were randomly assigned to groups that orally receive 900, 1200, and 1500 mg of ubiquinol or placebo daily for 14 days. Safety was assessed by examining the frequency and severity of adverse events. The levels of ubiquinol in plasma and total CoQ10 in peripheral blood mononuclear cells and cerebrospinal fluid were investigated.
Results
Thirty‐two participants provided informed consent to participate in this study. No clinically relevant changes in standard laboratory tests, physical examination, vital signs, or electrocardiogram attributable to ubiquinol administration were observed in any groups. The trough of plasma ubiquinol levels after repeated administration for 14 days reached a steady state, and the plasma ubiquinol levels in the 1500 mg/day‐administered group tended to be the highest.
Conclusions
High‐dose ubiquinol supplementation was shown to be safe and tolerated when administered orally to healthy adult males at a maximum dosage of 1500 mg/day for 14 days (UMIN Clinical Trials Registry number, UMIN000016695).
Förderung
- Japan Agency for Medical Research and Development
Zitieren
APA
Mitsui, J., Matsukawa, T., Tanaka, M., Saito‐Sato, N., Nakamoto, F. K., Yasuda, T., Naruse, H., Matsukawa, M. K., Ishiura, H., Nagase, M., Yamamoto, Y., Kuzuyama, H., Wada, I., Ga, T., Yamazaki, T., Moritoyo, T., & Tsuji, S. (2022). Randomized, double‐blind, placebo‐controlled phase 1 study to evaluate the safety and pharmacokinetics of high doses of ubiquinol in healthy adults. Neurology and Clinical Neuroscience, 10(1), 14-24. https://doi.org/10.1111/ncn3.12566
Vancouver
Mitsui J, Matsukawa T, Tanaka M, Saito‐Sato N, Nakamoto FK, Yasuda T, et al. Randomized, double‐blind, placebo‐controlled phase 1 study to evaluate the safety and pharmacokinetics of high doses of ubiquinol in healthy adults. Neurology and Clinical Neuroscience. 2022;10(1):14-24. doi:10.1111/ncn3.12566
BibTeX
@article{Mitsui2022,
author = {Mitsui, Jun and Matsukawa, Takashi and Tanaka, Masaki and Saito‐Sato, Naoko and Nakamoto, Fumiko Kusunoki and Yasuda, Tsutomu and Naruse, Hiroya and Matsukawa, Miho Kawabe and Ishiura, Hiroyuki and Nagase, Midori and Yamamoto, Yorihiro and Kuzuyama, Haruko and Wada, Ikue and Ga, Toshio and Yamazaki, Tsutomu and Moritoyo, Takashi and Tsuji, Shoji},
title = {Randomized, double‐blind, placebo‐controlled phase 1 study to evaluate the safety and pharmacokinetics of high doses of ubiquinol in healthy adults},
journal = {Neurology and Clinical Neuroscience},
year = {2022},
volume = {10},
number = {1},
pages = {14--24},
doi = {10.1111/ncn3.12566}
}
EUVIMED